Results 161 to 170 of about 259,945 (244)
Hepatocellular carcinoma (HCC)‐derived extracellular vesicles (EVs) enrich the metabolic enzyme ATP‐citrate lyase (ACLY). EV‐transferred ACLY enhances palmitate biosynthesis, increases the S‐palmitoylation and stability of multiple immune checkpoint proteins, augments the cellular immunosuppressive activity, and ultimately accelerates the malignant ...
Zhijun Liu +11 more
wiley +1 more source
The Role of PD-L1 in Lung Cancer: From Biology to Clinical Application. [PDF]
Lamghari H, Karkouri M.
europepmc +1 more source
A multifaceted chemical strategy, integrating bacterial tropism, metal‐ion interference therapy, and immunotherapy, resulted in significant tumor regression in murine models. A pioneering paradigm for the design of biohybrid materials was established, highlighting how sophisticated chemical engineering of living systems can unlock new avenues for ...
Tingting Zhang +7 more
wiley +1 more source
Development and Validation of a Multicyclic Peptide Targeting PD-L1 for Radiotheranostics. [PDF]
Meng L, Li X, Patel JS, Liang SH.
europepmc +1 more source
Bacterial Outer Membrane Vesicles in Potentiating Cancer Vaccines: Progress and Prospects
Bacterial outer membrane vesicles (OMVs) have emerged as versatile platforms for cancer vaccine development owing to their intrinsic immunostimulatory properties and high engineering flexibility. This review summarizes OMV biology, immune mechanisms, and engineering strategies that enhance vaccine efficacy, discusses key translational challenges, and ...
Jiabeini Zhang +9 more
wiley +1 more source
The role of PD‑1/PD‑L1 axis in liver diseases. [PDF]
Zeng Z +7 more
europepmc +1 more source
This study reveals that the Fgl2‐FcγRIIB signaling axis is a key mechanism by which MDSCs mediate tumor immune evasion. Tumor‐derived exosomes systemically activate MDSCs via this pathway, positioning this axis as a promising broad‐spectrum target for cancer immunotherapy.
Fenglin Lin +12 more
wiley +1 more source
Clinical Benefit of PD-1/PD-L1 Inhibitors as Standard First-Line Treatment in Low PD-L1-Expressing Advanced Solid Tumors: A Systematic Review and Meta-Analysis. [PDF]
Wu P +14 more
europepmc +1 more source
Vorinostat Potentiates Chemoimmunotherapy in Immune‐Enriched Pancreatic Cancer
Immune‐enriched pancreatic cancer does not confer a significant survival advantage. SAHA sensitizes these “hot” tumors to chemoimmunotherapy by disrupting a FASN/PARP9‐driven “metabolic trap” and enhancing CD8+ T cell function. A CD8high/FASNhigh/PARP9high signature identifies patients who are most likely to benefit from the “gemcitabine‐nivolumab‐SAHA”
Chen Chen +13 more
wiley +1 more source
Lactylation stabilizes PD-L1 to promote tumor immune evasion and cell growth. [PDF]
Liang L +7 more
europepmc +1 more source

